DPP-4 inhibitors in the treatment of type 2 diabetes
10.3760/cma.j.issn.1000-6699.2011.01.031
- VernacularTitle:DPP-4抑制剂在2型糖尿病治疗中的应用
- Author:
Ruya ZHANG
;
Juming LU
- Publication Type:Journal Article
- Keywords:
Dipeptidyl peptidase-4 inhibitors;
Glucagon-like peptide-1;
Diabetes mellitus,type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(1):后插1-后插4
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide-1 (GLP-1) can maintain glucose homeostasis, improve islet function,delay and even reverse deterioration of type 2 diabetes by several pathways.But shortly after secreting and releasing into the blood, endogenous intact GLP-1 is cleavaged by dipeptidyl peptidase-4 (DPP-4) into inactive forms.DPP4 inhibitors prevent the inactivation and enhance the physiological effects of GLP-1 through selectively suppressing the enzymic activity of DPP-4, resulting in reduction of HbA1C, fasting and postprandial plasma glucose in type 2diabetes mellitus.The favorable efficacy, safety, and tolerability of DPP-4 inhibitors, which have been well verified in numerous clinical trials and clinical practice for type 2 diabetes mellitus, render them a novel type of oral antidiabetic drugs.
